Company profile

Avivo Biomedical

Avivo Biomedical is a Canadian biotechnology company developing enzyme-enabled approaches intended to convert donated blood and organs to universal type O and improve the availability of urgent treatment options.

Request an introduction Add to Working List Download profile Visit company website

How to read the record

Know what is sourced, assessed, current or still unknown.

Public-source factA released source supports the statement.
Our assessmentA person reviewed where the evidence may point.
Evidence strengthThe label reflects the quality and depth of public support.
Last reviewedThe date shows when the record was checked most recently.
Not yet verifiedMissing information stays visible instead of being invented.

1 reviewed technology or offering

Avivo Biomedical’s Tech

Universal blood-type conversion platform

Enzyme-enabled blood and organ compatibility platform

Moderate evidence

Avivo develops enzyme-enabled methods intended to convert type-A blood cells and donor organs to universal type O, with public materials describing translational research and potential use in hospital, remote, emergency and trauma settings.

Core features

Blood-type conversion enzymes
Whole-blood conversion research
Organ-conversion research
Compatibility with existing clinical workflows

Defence applications

Emergency and trauma care
Remote care
Military medical support
Transplant medicine

Blood conversionEnzymologyTrauma careMedical biotechnologyUniversal donor

Explore this technology

See the missions and released public needs worth exploring

Where this technology may help

Our assessmentLimited public evidence

Edge Data Processing

A portable, workflow-compatible clinical technology for urgent or remote care could be relevant to distributed support contexts; this is a derived assessment and is not a public procurement claim.

Supporting sourcesAvivo company and technology profile

This is a reviewed public-source assessment. It is not procurement eligibility, endorsement, customer interest, or classified demand.

2 public sources

Evidence & sources

Avivo company and technology profile
Avivo Biomedical · official organization profile
A portable, workflow-compatible clinical technology for urgent or remote care could be relevant to distributed support contexts; this is a derived assessment and is not a public procurement claim.
Avivo media and research updates
Avivo Biomedical · official company news
Avivo's public media page records NATO DIANA 2026 cohort selection and recent translational research announcements, while its company page describes ongoing work toward blood- and organ-type conversion.

North Signal · Weekly briefing

See what Canada is building next.

One concise weekly briefing on newly mapped Canadian capabilities, released public needs, and defence developments worth following.

Weekly. Evidence-led. Unsubscribe anytime. Read a sample.